How does ibrutinib work in CLL?

Ibrutinib also eliminates the complete activation of Btk by inhibiting Btk autophosphorylation at Tyr-223. This inhibition prevents downstream activation of theBCR pathway and subsequently blocks the growth, proliferation, and survival of malignantB cells. Ibrutinib is used to treat chronic lymphocytic leukemia(CLL)/small lymphocytic lymphoma(SLL), chronic lymphocytic leukemia in patients with 17p deletion >(CLL)/Small lymphocytic leukemia(SLL) and WaldenströMacroglobulinemia(WM). If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to learn more about high-quality overseas drugs for you.